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Abstract 
Background: 
Non-steroidal anti-inflammatory drugs are among the most widely used medications for the 
treatment of various inflammatory disorders. However, the GI toxicity of NSAIDs limits their 
usefulness. Conventional NSAIDs prodrugs activated via enzymes distributed throughout the 
body. These metabolic enzymes can be affected by various factors such as age, health conditions 
and gender. Therefore, it is difficult to predict the bioconversion rates. A novel strategy to 
convert the prodrug to its active parent drug has been developed, whereby intramolecular 
mechanism utilized to release the drug from its corresponding prodrug. 
Objectives: 
The main goal of our work is to synthesize diclofenac and mefenamic acid prodrugs and codrugs 
lacking the bitter taste, gastric adverse effects. In addition, the proposed diclofenac and 
mefenamic prodrugs and codrugs should have the potential to undergo a chemical and not 
enzymatic driven cleavage, and release the active parent drug in a controlled manner. 
Methods: 
The structures of the synthesized prodrugs were confirmed and characterized by spectral analysis 
techniques. The release pattern of parent drug from prodrug was also studied by HPLC method. The 
kinetics of the prodrugs and codrugs hydrolysis was studied in four different buffer solutions at 
1NHCl, pH 2.5, pH 5.5, and pH 7.4. 
Results: 
Novel bitterless prodrugs of mefenamic acid and diclofenac were synthesized. Codrugs of each 
of mefenamic acid and diclofenac with tranexamic acid were synthesized. The kinetic results of 
synthesized NSAIDs prodrugs revealed that hydrolysis rate is highly affected by the pH of the 
medium. The t1/2 of mefenamic dimethylamine at the pH of the stomach was 10 hours while it 
was stable at pH 2.5, pH 5.5 and pH 7.5. The experimental t1/2 values of diclofenac benzyl were 
4 hours and 1 hour at 1NHCl and pH7.4 respectively, while it was entirely stable at pH 2.5 and 
pH5.5. Mefenamic tranexamic released both drugs in 1 hour at 1 NHCl. However, the release of 
the drugs from mefenamic tranexamic at pH 2.5, pH5.5, and pH7.4 was negligible. Diclofenac 
tranexamic at 1 NHCl was found to be cleaved within 30 hours. 
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Chapter One 
1. Introduction 
 
1.1 Prodrug Background 
 
Every drug is characterized by its biological and physicochemical properties. Some 
of the marketed drugs have many drawbacks in their performance that result in an 
inefficient delivery and unwanted side effects. The physicochemical, biopharmaceutical 
and pharmacokinetic properties of these drugs should be improved in order to increase 
their usefulness and to increase their utilization in clinical practice [1, 2]. 
In the past few decades, there has been a steady improvement in the pharmaceutical 
industry to facilitate the drug discovery phases. Many methods were developed to find 
new chemical entities that provide the desirable therapeutic effect with minimal 
unwanted side effects. However, this strategy is time consuming, costly and requires 
screening of thousands of molecules for biological activity of which only one might 
enter the drug market. One of the most powerful, attractive and promising method is the 
prodrug design in which the active drug molecule is linked to a promoiety to alter its 
undesired properties. Unfortunately, prodrugs are often considered when problems 
encountered with the parent drug. The design of an appropriate prodrug should be 
considered in the early stages of preclinical development and should not be viewed as a 
last resort [3, 4]. 
The prodrug term introduced for the first time by Adrien Albert  in 1958 [5]. 
Prodrugs are chemically modified versions of the original drugs designed  to exert the 
desired pharmacological effect after an enzymatic and or chemical transformation once 
they have been  administered into the body [1, 6]. The rationale behind the use of 
prodrug is to alter the physicochemical, pharmacokinetic and biopharmaceutical 
properties of the compound. By chemical modifications on the active agent, the prodrug  
can overcome various  barriers  such as low oral drug absorption, lack of site specificity, 
chemical instability, toxicity and poor patient acceptance (bad taste, odor, pain at 
injection site, etc) [7]. 
The prodrug concept was used for the first time in the mid twentieth century when 
Parke-Davis Company conducted a modification of chloramphenicol structure to 
improve its unpleasant taste and poor solubility in water. As a result of this study two 
chloramphenicol prodrugs were synthesized: chloramphenicol sodium succinate having 
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a good water solubility for use in IV, IM and ophthalmic administration and 
chloramphenicol palmitate to be administered in the form of suspension for children    
[8, 9]. 
Prodrugs can be classified based on the type of carrier attached to the drug. There 
are two main classes: (1) carrier linked prodrugs; this term of prodrugs implies a 
bioreversible covalent linkage between an active drug and a carrier moiety. In most 
cases, prodrug linkers are removed by an enzymatic or chemical reaction (esters or 
labile amide). Ideally the linker should be nontoxic, easy to synthesize at low cost, 
undergo biodegradation to non-active metabolite. Carrier-linked prodrugs can be further 
subdivided into: (a) bipartite which is composed of one carrier (promoiety) attached 
directly to the drug, (b) tripartite which utilizing a spacer between the drug and a 
promoiety. In some cases bipartite prodrugs may be unstable due to inherent nature of 
the drug-promoiety bond. This can be overcome by designing a tripartite prodrug and(c) 
mutual prodrugs, which are consisting of two drugs linked together [10]. 
2) Bioprecursors prodrugs: inactive compounds  that contain no promoiety but is rather 
based on the action of metabolism by processes such as oxidation, reduction,  sulfation 
and phosphorylation activations to create the desired active agent [11]. 
Many intrinsic and extrinsic factors can influence the bioconversion of prodrugs via 
enzymes. The rate of bioconversion is not always predictable and can be affected by 
different factors such as age, gender, and health condition [12, 13].                                        
      There are two major challenges facing the prodrug approach: prodrugs designed to 
be activated via hydrolysis such as peptidases, phosphatases, and carboxylesterases, 
might be tackled by a premature hydrolysis during the absorption phase in enterocytes 
of gastrointestinal tract, which could produce more polar and less permeable prodrugs  
and are more likely to be refluxed by passive and carrier mediated processes into the 
lumen  which results in  a reduced bioavailability (50%). On other hand, cytochrome 
P450 enzymes are responsible for 75% of the enzymatic metabolism of prodrugs. There 
is accumulating evidence that  genetic polymorphisms of P450 enzymes contribute to 
variability in  prodrug activation which has an impact on the efficacy and safety of 
designed prodrugs [14]. 
Nowadays, a novel chemical prodrug approach utilized the mechanisms for 
intramolecular processes to design prodrugs which can chemically and not 
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enzymatically be cleaved to release the active parent drug in a controlled manner. In this 
approach the prodrugs design is based on intramolecular processes (enzyme models) 
using molecular orbital and molecular mechanics methods and correlations of 
experimental and calculated reactions rates and the rate of the drug release from its 
prodrug is controlled by the nature of the linker bound to the parent active drug[15, 16]. 
 
1.2  Applications of prodrugs 
1.2.1 Improvement of taste 
 
Taste is an important factor in the development of dosage forms. Unacceptable taste 
of certain drugs may often affect patient compliance especially in pediatric and geriatric 
populations. Medicines dissolve in saliva and interact with taste buds (G-protein 
coupled receptor-type T2R)  on the tongue to give bitter taste [17]. Conventional taste 
masking methods such as the use of sweeteners, and flavoring agents are often 
inadequate in masking the taste of highly bitter drugs. To overcome this problem there 
is a need for orally administered bitter drugs formulated as prodrugs to mask their bitter 
taste. It was reported that a bitter tastant molecule requires a polar group having 
hydrogen bonding capability and a hydrophobic moiety. For example, paracetamol, an 
antipyretic and pain killer drug, has a bitter taste, it is believed that the phenolic 
hydroxyl group of paracetamol interacts by hydrogen bonding with bitter taste 
receptors. Therefore, blocking the hydroxyl group with a suitable linker could inhibit 
the interaction and mask the bitter taste of paracetamol [18, 19]. 
 
1.2.2  Improvement of bioavailability 
 
Low bioavailability and low water solubility are frequent problems in drug 
development. Oral drug bioavailability is critical for the development of new drugs, 
because low oral absorption leads to inter- and intra-patient variability [20]. Oral 
bioavailability of lipophilic drugs depends on the dissolution in the gastrointestinal 
fluids, and polar drug's bioavailability depends on the transport across gastrointestinal 
mucosa. Therefore prodrugs are designed to increase or decrease lipophilicity. 
Approximately more than 30% of discovered drugs have poor aqueous solubility. Some 
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times formulation techniques such as salt formation andsolublizing excepients can't 
provide adequate solubility. Prodrugs are an alternative to  increase the aqueous 
solubility of parent drugs by improving dissolution rate via ionizable or polar neutral 
functions attached to the parent drug such as phosphates, amino acids or sugar moieties 
[21]. 
Absorption of drugs through several lipid membranes has a significant influence on 
drug efficacy. Increasing lipophilicity of polar drugs promotes membrane permeation 
and oral absorption. Oral route of administration is the most common and preferred 
route of administration for the majority of drugs. Prodrugs are used to increase 
lipophilicity by masking the polar moiety of the drug so that the drugs are available for 
oral administration, ocular or topical drug delivery [22]. 
 
1.2.3 Overcoming toxicity problems 
 
Many therapeutically active agents have adverse reactions that would limit their 
clinical use. Adverse drug reactions can change the structure and function of cells, 
tissues, and organs. Reduced toxicity can be accomplished by targeting drugs to desired 
cells via site selective drug delivery. Based on prodrug strategy, successful prodrug 
must be precisely transported to the site of action, where it should be transformed into 
the active drug to produce the therapeutic effects.  Reduced toxicity can sometimes be 
accomplished by altering the structure of the parent drug. For example, esterification of 
non-steroidal anti-inflammatory drugs suppress their ulcerogenic activity [23]. 
 
1.2.4  Enhancement of chemical stability 
 
Prodrug provides chemical stability for drugs that may destabilized at long-term 
storage. If a drug is chemically very unstable and the instability problem cannot be 
resolved by formulation means, it is sometimes possible to develop a prodrug with 
enhanced stability over the parent drug. This strategy can be used by changing the 
functional group responsible for the instability [24].  
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1.2.5 Protecting from rapid metabolism and excretion 
 
Extensive metabolic and excretion pathways cause low oral bioavailability of drugs; 
high first pass effect in gastrointestinal tract and liver has been bypassed by prodrug 
strategy. This is usually done by masking metabolically labile but pharmacologically 
essential functional groups. The addition of lipophilic promoieties can decrease the 
solubility of many drugs and prolong the duration of action of very water-soluble drugs 
[25]. 
1.3  Codrug approach 
 
In some cases, two pharmacologically active drugs can be coupled together in a single 
molecule, called a codrug. In such a way that each drug acts as a promoiety for the other 
and vice versa. The codrug approach offers an efficient tool for improving the clinical 
and therapeutic effectiveness of a drug. Linking the two drugs moieties may have some 
additional biological  action  lacking  in  the  parent  drug,  thus ensuring  some  
additional  benefits or providing ―synergistic‖ effects. Mutual prodrug has  given a 
successful results in  case  of  well accepted  and  useful  drugs with  undesirable   
properties  like absorption, poor bioavailability no specificity, and GIT toxicity. In the 
last few decades, mutual prodrug approach contributed in different therapeutic areas and 
a list of patents was developed in this field. The main objective of mutual prodrug 
designing is to bring both active drugs to their active sites with the desired 
pharmacological action while minimizing toxicological events [26]. 
In combination therapy for the management of many diseases, the therapeutic agents 
can be  co-administered in separate dosage forms, however, the co-drug offers a 
potential advantages in delivering co-administered agents as a single chemical entity to 
increase the  patient compliance [27]. The same as conventional prodrug, a mutual 
prodrug is converted into the component active drugs within the body through 
enzymatic and/or chemical reactions. The preferred linkage between the first and the 
second components of the codrug is the one that could be cleaved under physiological 
conditions. 
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1.4  NSAIDs 
 
Non steroidal anti-inflammatory drugs are among the most widely used therapeutic 
agents in modern medicine. NSAIDs are very effective in the alleviation of pain, signs 
of inflammation: fever, swelling and redness [28]. Due to their anti-inflammatory effect, 
NSAIDs are commonly used to treat chronic health problems such as rheumatoid arthritis 
and lupus. However, the clinical usefulness of NSAIDs is still restricted by their GI side 
effects like gastric irritation, ulceration, bleeding, and perforation and in some cases 
may develop into life threatening conditions. NSAIDs exert their pharmacological 
action by inhibiting the production of prostaglandins by non-selectively blocking the 
COX enzymes (COX-1 and COX-2), causing analgesic, antipyretic, and anti-
inflammatory benefits.COX-1 act as a housekeeping enzyme by regulating normal 
physiological processes such as the maintenance of gastric mucosal integrity,  platelet 
aggregation and  kidney function, whereas COX-2 is inducible and plays a major role in 
prostaglandin biosynthesis in inflammatory cells [29]. 
It is a well-accepted fact that the gastrointestinal toxicity of NSAIDs is mainly 
related to the mechanism of action of these agents. They are attributed to direct and/or 
indirect mechanisms. The free carboxylic group present in NSAIDs is thought to be 
responsible for direct local irritation of gastric mucosa. While the systemic inhibition of 
COX-1 enzyme induces indirect NSAIDs side effect, generalized inhibition of COX-1 
after NSAIDs absorption mediates the gastro-intestinal toxicity. Despite the fact that 
this effect is decreased with selective COX-2 inhibitors, some patients undergoing 
chronic NSAIDs treatment demonstrated  serious cardiovascular side effects [30, 31]. 
NSAIDs related gastrointestinal side effects categorized into three groups [32-34]: 
(I) Subjective symptoms:  like heartburn, abdominal pain, nausea and dyspepsia 
developed in 15 to 40% of NSAIDs users. 
(II) Superficial gastrointestinal mucosal lesions such as erosions and asymptomatic 
ulcers, occurring in 5 to 20% of NSAIDs users. 
(III) Serious gastrointestinal ulcers leading to life-threatening complications like 
perforation, symptomatic ulcers, and bleeding (perforation, ulcer, bleeding) 
occurring in 1% to 2% of chronic NSAIDs users, with an associated mortality 
rate of 10% to 15%. 
8 
 
Nearly all NSAIDs promote gastric ulceration and gastrointestinal bleeding.  Among 
patients who chronically use NSAIDs 65% will develop intestinal inflammation  and up 
to 30% will develop gastro duodenal ulceration [35, 36]. 
 
1.4.1 Diclofenac 
 
Diclofenac is 2-(2,6-dichloranilino) phenylacetic acid. It is used to relieve  acute or 
chronic pain states in which there is an inflammatory component like rheumatoid 
arthritis, osteoarthritis and in the treatment of pain resulting from minor surgery, trauma 
and dysmenorrheal [29]. It is one of the most frequently used NSAIDs since its 
introduction in 1974.Currently,diclofenac is  the eighth largest-selling drug in the world 
[37]. Diclofenac is rapidly absorbed following oral administration, and undergoes 
extensive first-pass metabolism resulting in a systemic bioavailability of approximately 
50% with a half-life of approximately 2 hours. 
O
OH
NH
Cl
Cl
 
Figure ‎1.1: Chemical structure of diclofenac. 
 
1.4.2 Mefenamic acid 
Mefenamic acid (MA) 2-[(2,3-dimethylanilino]-benzoic acid is a member of anthranilic 
acid derivatives. It possesses anti-inflammatory effect due to its ability to inhibit COX 
enzymes and phospholipase A2. It is typically prescribed for oral administration to relieve 
mild to moderate pain including headaches, dental pain, and muscular aches and most 
commonly used as analgesic to relive the pain associated with dysmenorrhea. The drug has 
a relatively short half-life of 2 hours. Mefenamic acid is available as 250mg capsules [38]. 
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Figure ‎1.2: Chemical structure of mefenamic acid. 
 
 
1.5  Tranexamic acid 
 
(trans-4 (aminomethyl) cyclohexane carboxylic acid) is a synthetic derivative of the 
amino acid lysine that exerts its antifibrinolytic activity through competitive inhibition 
of the lysine binding site on plasminogen molecule. Thus, inhibits the activation of 
plasminogen to plasmin; plasmin is an enzyme used to degrade fibrin clot [39]. 
Tranexamic acid is an effective agent to treat excessive blood loss in different health 
condition and in  surgeries such as coronary artery bypass, hip and knee replacement 
and liver transplantation [40]. It is an important agent to reduce mortality and morbidity 
caused by postpartum haemorrhage (PPH). It was  reported in a Cochrane review on 
treatment of PPH that tranexamic acid could potentially have prevented some PPH cases 
if it was given to women with the risk factors for PPH[41]. 
Bleeding in trauma patients has also been treated with tranexamic acid. CRASH-2 
study concluded that all caused mortality, relative risk and relative death due to bleeding 
were reduced with a tranexamic acid group more than a placebo group [42]. 
Tranexamic acid considered safe non-hormonal therapy to treat dysmenorrhea. It is 
usually prescribed with NSAIDs to treat heavy painful bleeding in women during 
menstrual cycle to improve women`s life quality [43]. A randomized controlled trial   
concluded that oral tranexamic acid is effective in decreasing blood loss during 
menstrual cycle by 40% [44].  Tranexamic acid acts within two to three hours after oral 
administration and immediately after intravenous administration. It has a Low 
bioavailability of (34%). 
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Figure ‎1.3: Chemical structure of tranexamic acid. 
 
1.6  Research Problem 
 
Although NSAIDs are potent anti-inflammatory drugs, their prolonged 
administration has been limited by the high incidence of gastrointestinal erosions. GI 
mucosal injury is generally believed to be caused by two different mechanisms:(i) local 
action  exerted by direct effect of the drug on gastric mucosa caused by free carboxylic 
acid  group attributed to the local inhibition of prostaglandin synthesis. While indirect 
effect is attributed to ion trapping in mucosal cells or back diffusion of H
+
 ions from the 
lumen into the mucosa and (ii) generalized systemic action following absorption, that is 
believed to be as a result of an inhibition of COX 1 enzymes [45]. 
Intolerance of GI side effects leads to withdrawal rates of about 10%. Also, 
nonselective NSAID users are four to eight times more likely to develop gastro 
duodenal ulcers during therapy. Elderly patients are considered most at risk to develop 
ulcerogenic events from NSAIDs [46]. Lanas et al. have concluded that more than 90% 
of osteoarthritis patients treated with NSAIDs are at increased GI risk, among which 
60% of them at high risk [47]. 
Much of preventive strategies have been developed in order to decrease NSAIDs GI 
toxicity. These are either directed at maintaining the integrity of the stomach wall and 
mucous layer, such as the use of  COX-2 selective NSAIDs and the concomitant 
administration of prostaglandin analogues, or alternatively  inhibiting the secretion of 
gastric acid, such as concomitant use of proton pump inhibitors (PPI) or histamine H2 
receptor antagonists [48]. The use of certain gastro protective agents  with NSAIDs has 
been proven to reduce serious GI adverse events, but adds to the cost of NSAID therapy 
[49]. Selective COX-2 inhibitors, such as celecoxib, have been clinically introduced as  
(GI)-sparing NSAIDs. However, these compounds are not devoid of side effects, as they 
can cause cardiovascular complications. 
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Significant amount of attention have been received from clinicians and healthcare 
providers since these  GI side effects are costly, require hospitalization, and may be fatal 
[50].  Few studies have estimated mortality resulting from GI complications of NSAIDs 
and found the deaths to be  widely varied from 3,200 to higher than 16,500 deaths  per 
year in the United States [51]. 
 
Figure ‎1.4. Mortality statistics for different drugs and diseases in the united states   
1997[52]. 
On the other hand, NSAIDs have unpleasant bitter taste associated with numbness 
of the tongue, which leads to lack of patient compliance especially in pediatrics and 
geriatrics patients, creating a serious challenge to pharmacists. Different techniques 
such as the use of sweeteners, amino acids and flavoring agents have been developed to 
overcome the bitter taste. These approaches were found to be inadequate and could not 
overcome the problem [53]. 
In modern medicine, NSAIDs with tranexamic acid are the first line therapy to treat 
pain associated with bleeding. It has been shown to be effective in reducing heavy 
menstrual bleeding and pain especially in women using IUDs. Giving such co-
administered drugs having complementary pharmacological activities in the form of a 
single chemical will increase patient compliance. Abnormal uterine bleeding and pain 
are the most common medical reasons for premature discontinuation of the intrauterine 
device (IUD). The IUD is the most common method of reversible contraception 
worldwide (147million current users), so premature discontinuation affects large 
numbers of women. Each year, almost 40 million women have an IUD inserted. Among 
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these,  5% to 15%  discontinue IUD use within one year because of bleeding and pain 
[54]. 
Using codrug approach could increase tranexamic acid bioavailability while eliminating 
NSAIDs GI adverse effects. This can be achieved by making a covalent linkage 
between tranexamic acid and diclofenac or mefenamic acid which is expected to 
increase the lipophilicity of tranexamic acid.  
The major problem with conventional NSAIDs prodrugs is the difficulty in predicting 
their bioconversion rates, and thus their pharmacological or toxicological effects. These 
prodrugs are metabolized via enzymes distributed through the body. Many intrinsic and 
extrinsic factors such as genetic polymorphisms, age-related physiological changes, and 
drug- drug interactions can affect the process.  
Until now there is no NSAIDs prodrugs formulated that can alleviate the potential side 
effects completely. Therefore, there is a need to develop bitterless, safe NSAIDs devoid 
of gastrointestinal side effects, and have the potential to undergo conversion to their 
parent drugs via intramolecular reaction in a controlled manner. 
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1.7 General Objective 
 
The main goal of this thesis was to synthesize, characterize and evaluate the kinetics 
for the following novel prodrugs: diclofenac benzyl and mefenamic dimethylamine, and 
the codrugs: diclofenac tranexamic and mefenamic tranexamic. 
 
Specific objectives: 
1. To synthesize mefenamic and diclofenac prodrugs, as a gastro sparing NSAIDs 
devoid of ulcerogenic side effects, and to mask their bitter taste by esterification or 
amidation of their free carboxyl group using different linkers. 
2. To synthesize NSAID codrugs by conjugating mefenamic acid or diclofenac with 
tranexamic acid in order to ameliorate the gastric irritation by temporary blockage of the 
free carboxylic group present in the NSAID till its systemic absorption, increase  
tranexamic acid bioavailability and  to produce a chemical combination therapy to treat 
disorders which involve pain and bleeding like menorrhagia. 
3. To characterize the proposed prodrugs and codrugs using several characterization 
techniques. 
4.  To examine the prodrugs kinetics in different buffer conditions (1 NHCl, pH 2.5, 
pH5.5, pH 7.4). 
5. To investigate the structural factors associated with high reactivity in the hydrolysis, 
and how the structural features of the prodrug linker can affect the interconversion 
process of the synthesized prodrugs and co drugs. 
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Chapter Two 
2. Literature Review 
 
2.1  NSAIDs prodrugs 
 
    In the past few years, extensive research has been oriented towards improvement of 
therapeutic efficacy of drugs through removal of their undesirable effects. Design and 
synthesis of NSAIDs prodrugs is becoming more popular, successful and have been 
given much attention by medicinal chemists. Many efforts have been made to 
synthesize  NSAIDs prodrugs via masking the carboxylic acid group  by forming ester 
and amide prodrugs [55, 56].  
The literature shows clearly that most of the effort to design NSAIDs prodrugs was 
devoted to protect the gastrointestinal tract from ulcerogenic effects. During the past 
years numerous NSAIDs prodrugs have been synthesized to overcome the 
gastrointestinal side effects. Further studies to develop promising new NSAIDs 
prodrugs are in progress. In the following sections a number of examples of NSAIDs 
prodrugs will be discussed. 
2.1.1  Mefenamic acid prodrugs and codrugs 
 
During the past seventeen years attempts have been made to overcome the 
gastrointestinal side effects associated with the use of mefenamic acid. In 1997 Jilani et 
al. have synthesized several hydroxyl ethyl esters of diclofenac and mefenamic acid and 
studied their stability in 1N HCl, buffer pH 7.4 and human plasma. Their study revealed 
that mefenamic acid prodrugs were much more stable than their corresponding 
diclofenac prodrugs. The t1/2 values for mefenamic acid prodrugs were 38 hours in 
buffer pH 10 and 7.8 hours in plasma and that of diclofenc prodrugs were 22 hours and 
1.12 hours, respectively. Based on this result they concluded that mefenamic ester 
prodrugs are not suitable for use as prodrugs due to their high stability in plasma [57]. 
In 2002, Tantishaiyakul et al. have synthesized a mefenamic-guaiacol ester prodrug 
by reacting mefenamic acid, guaiacol, N,N′-dimethylaminopyridine, and                          
N,N′-dicyclohexyl carbodiimide. The physicochemical properties, stability and transport 
across Caco-2 monolayers for the synthesized prodrug were researched. The prodrug 
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has shown to be completely stable in aqueous buffer solutions of pH 1-10. However, it 
underwent hydrolysis in the presence of porcine liver esterase and Caco- 2 homogenate. 
The transported amount of the ester was 14.63% after 3 hours with a lag time of 23 
minutes. The Papp for the ester was 4.72 × 10
-6
 cm s
-1
. This value suggests that the 
prodrug absorption was  moderate [58]. 
In 2005, Almasirad et al. have made a number of mefenamic acid prodrugs by 
which the non-steroidal anti-inflammatory drug was attached to N-arylhydrazone 
derivative. The aim of their study was to obtain new compounds having analgesic and 
anti-inflammatory activity without GI side effects. The synthesized prodrugs were 
tested for analgesic and anti-inflammatory activities by abdominal constriction 
(writhing test) and carrageenan-induced rat paw edema tests, respectively. Their study 
revealed that most of the synthesized prodrugs induced significant reduction in the 
writhing response compared to the control samples [59]. 
In  2005,  Khan et  al. reacted  mefenamic  acid  with  1,  2,  3-trihydroxy  propane  
1,  3-dipalmitate/stearate  to  provide  new  mefenamic  acid  ester  prodrugs.  The aim 
of their study was   to   make   novel   mefenamic   acid   prodrugs   lacking   the   
gastrointestinal   side   effects associated with their parent drug, mefenamic acid. The 
synthesized prodrugs were tested for gastric toxicity, anti-inflammatory activity by the 
carageenan induced paw oedema test and analgesic activity by the acetic acid induced 
writhing method. The cleavage rate of the ester prodrugs to their parent active drug was 
studied at pH 3, 4, 5 and 7.4 and monitored by HPLC method. The kinetic results 
revealed very low hydrolysis rate at pH 5 when compared to pH 7.4.  This  result  
indicates  that  the  drug  release  from  the  prodrugs  in  the  pH  of  stomach  was 
negligible; however, the release of mefenamic acid at pH 7.4 was in adequate amounts 
[60]. 
In 2007, Dev.et al. have synthesized  mefenamic  acid-β-cyclodextrin  prodrug.  The 
primary hydroxy group of β- cyclodextrins was used to block the free acid group of 
mefenamic acid. The synthesis consisted of several protection and deprotection steps. 
The study demonstrated that mefenamic acid-β-cyclodextrin prodrug has retained its  
pharmacological  activity  as  was  evident  by  the  percentage  inhibition  of  oedema 
and  in acetic  acid  induced  writhing  method  and  comparison  with  the  activity  of  
its  active  parent drug.  In  addition,  the  study  showed  that  the  maximum  activity  
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of  the  ester  prodrug  was obtained after 6  hours  indicating that there  is  no drug 
absorption  in the  stomach. Further, in vitro studies showed the ester was completely 
stable in simulated gastric and intestinal fluid whereas it underwent complete hydrolysis 
in rat fecal contents representing the colon. Ulcerogenicity  studies  showed  that  the  
ester  prodrug  is  not  ulcerogenic  indicating  that masking   the   carboxyl   group   in   
mefenamic   acid   is   a   good   approach   to reduce   the ulcerogenicity, a major side 
effect of the active parent drug, mefenamic acid[61]. 
In 2009, Rasheed et al. have synthesized mefenamic amide prodrugs by an 
amidation reaction of methyl esters of amino acids such as histidine and tryptophan with 
mefenamic acid. The goal of their study was to mask the free hydroxyl group of 
mefenamic acid which is responsible for the adverse effects of gastrointestinal origin 
associated with the use of the NSAIDs drugs. The hydrolysis rates, anti-inflammatory 
and analgesic activities as well as ulcer index of the synthesized amide prodrugs were 
investigated. The results indicated marked reduction of ulcer index and comparable anti-
inflammatory activity of the prodrugs as compared to mefenamic acid. In addition, the 
amide prodrugs showed excellent pharmacological response and encouraging hydrolysis 
rate both in SIF and SIF+ 80% human plasma. Based on these results the authors 
concluded that both amide prodrugs are more efficient than their active parent drug and 
are advantageous due to the fact that they possess lesser gastrointestinal side effects 
than mefenamic acid [62]. 
In 2010, Rasheed et al. have synthesized two mefenamic acid-amide prodrugs, 
mefenamic acid-tyrosine and mefenamic acid-glycine via multi-step synthesis which 
involved protection and deprotection reactions. Pharmacological activity test and kinetic 
studies on both prodrugs were carried out. The two prodrugs kinetic studies were 
accomplished in simulated gastric fluid, simulated intestinal fluid, and 80% plasma. In 
addition, the analgesic, anti-inflammatory, and ulcerogenic activities for both prodrugs 
were evaluated. Mefenamic acid glycine prodrug showed analgesic activity of 86%, and 
both mefenamic acid-tyrosine and mefenamic acid-glycine prodrugs showed more 
efficient anti-inflammatory activity (74% and 81%, respectively) than that of their 
parent drug, mefenamic acid (40% ). Moreover, the study indicated that the average 
ulcer index of the two newly synthesized prodrugs was lower (9.1 and 4.5) than that of 
mefenamic acid (24.2). Based on the study results the authors concluded that both 
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prodrugs are more efficient than mefenamic acid and are advantageous since their 
gastrointestinal side effects are lesser than of their parent drug [63]. 
In 2011, Uludag et al. have synthesized ibuprofen, ketoprofen, and mefenamic acid 
ester and amide prodrugs and they investigated their pharmacological activities and 
stability in physiological media. Their findings revealed that the synthesized prodrugs 
were completely stable in simulated gastric (SGF, pH 1.2) and intestinal fluids (SIF, pH 
6.8). Furthermore,  they  found  that  these  prodrugs  were  more  lipophilic  than  their  
parent  active drugs,  thus  resulting  in  higher  absorption  than  their  parent  drugs.  
Based  on  the  lack  of  the hydrolysis  of  these  prodrugs  by  esterases  and  amidases  
they  concluded  that  these  NSAID derivatives  have  potent  analgesic  and  anti-
inflammatory  activity  themselves  and  lack  any gastrointestinal  side  effects  (non- 
ulcerogenic).  These  results  were  supported  by  docking experiments of the 
synthesized prodrugs with the active sites of esterases and amidases which revealed a 
strong binding between the prodrugs and enzymes [64]. 
In 2011, Velingkar et al. synthesized a number of mefenamic acid codrugs with and 
without spacer. The synthesized codrugs were tested for anti-inflammatory activity by 
carrageenan induced rat paw edema method; for analgesic activity by Eddy’s hot plate 
and tail-flick method; and for ulcerogenicity and acute oral toxicity. The tests results for 
thecodrugs revealed efficient analgesic and anti-inflammatory activity and a lack of 
ulcerogenicity. Hydrolysis studies demonstrated that the codrugs were stable at pH 1.2, 
indicating a lack of cleavage of the codrugs in the stomach. However, in human plasma 
(pH7.4) the codrugs released 80% of the parent drug upon hydrolysis, whereas much 
lower percentage of the drug was released in aqueous buffer of 7.4, suggesting that the 
rate of hydrolysis in human plasma was markedly accelerated when compared to that in 
aqueous buffers [65]. 
In 2012, Mahdi et al. have synthesized a number of NSAIDs- gabapentin codrugs by 
which the two active parent drugs were connected by glycol spacers to reduce the 
gastrointestinal adverse effects associated with the use of NSAIDs. The hydrolysis of 
the ester bond connecting the two drugs via glycol in two different non enzymatic 
buffers at pH 1.2 and 7.4, as well as in 80% human plasma was monitored by HPLC. 
The codrugs connected via ethylene glycol spacers showed complete stability at buffer 
solutions with half-lives ranging from about 8–25 hours, whereas they underwent 49%–
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88% hydrolysis (within 2 hours) in 80% human plasma. The kinetic study results of 
some of the codrugs indicate that these compounds may be stable during their passage 
through the GIT until reaching the blood circulation[66]. 
In 2013, Shah et al. synthesized a novel codrug consisting of paracetamol and 
mefenamic acid with the aim to reduce the ulcererogenic adverse effects associated with 
the use of NSAIDs. The codrug was completely characterized by standard methods, its 
stability at different pH values was investigated and its pharmacological properties were 
evaluated. The kinetic study of the codrug was followed by HPLC at pH 2, pH 7.4 as 
well as in human plasma. The kinetics results showed the codrug to be stable at pH 2 
and pH 7.4; however, it underwent cleavage to the parent drugs in human plasma with 
hydrolysis rate of 1.8908 x 10
4
s
-1
and half-life (t1/2) of 61.07 minutes, indicating rapid 
hydrolysis in plasma to release the two parent drugs. The pharmacological activities 
(anti-inflammatory, analgesic and ulcerogenic) of the codrug were evaluated. The 
ulcerogenic reduction in terms of gastric wall mucosa, hexosamine and total proteins 
were also determined in glandular stomach of rats. The results revealed that the codrug 
has an ulcer index lower than the parent drug, indicating low ulcerogenic side effects 
[67]. 
In 2014, Dhokchawle et al. have synthesized a number of mefenamic acid prodrugs 
by which the free carboxyl group in mefenamic acid was connected via a covalent bond 
with natural compounds, eugenol and vanillin. The synthesized ester prodrugs were 
fully characterized by standard methods and by solubility studies, partition coefficient 
and hydrolytic studies. The synthesized prodrugs were tested for their anti-inflammatory 
analgesic and ulcerogenic activity. The tests results revealed that the synthesized 
prodrugs have shown retention of the anti-inflammatory activity with a reduced 
ulcerogenicity when compared to their active parent drug, mefenamic acid [68]. 
In 2014, Kemisetti et al. have synthesized mefenamic acid prodrugs by which the 
NSAID drug was covalently attached to either polyethylene glycol 1500 or polyethylene 
glycol 6000 via a glycine spacer. The synthesized prodrugs were fully characterized and 
their hydrolysis at buffers of pH 1.2 and 7.4 were investigated. In addition, their anti-
inflammatory activity using Carrageenan induced rat paw edema method and 
ulcerogenicity using Pylorus ligation method were tested. The study results 
demonstrated that the hydrolysis rates of the prodrugs at pH 7.4 were higher than that at 
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pH 1.2 and the anti-inflammatory activity of the prodrugs was comparable to that of 
their active parent drug, mefenamic acid. Based on these results the authors concluded 
that the synthesized prodrugs possess anti-inflammatory activity as well as good ulcer 
protecting activity and can be used as a better replacement to their parent NSAID drug 
[69].  
 
2.1.2  Diclofenac prodrugs and codrugs 
 
In 1993, morpholinoalkyl esters of diclofenac were synthesized and their hydrolysis 
in phosphate buffer pH 7.4 and plasma of rats was evaluated. The prodrugs were found 
to have better absorption than their parent drug and they underwent cleavage in fast 
rates. In addition, the study showed that  in vivo irritation of gastrointestinal mucosa of 
rat was significantly lower using these prodrugs compared to that after a single and 
chronic oral administration of diclofenac (the active parent drug) [70]. 
Tabrizi and coworkers have made several diclofenac prodrugs by attaching 
diclofenac to polychloromethylstyrene, polyvinyl chloroacetate and polyethylene glycol 
through a labile ester bond. The group found that these polymers are useful as 
polymeric prodrugs while the polyvinyl chloroacetate was evaluated as a good carrier 
for in vivo release of the drug. The hydrolysis of polymer-drug conjugates in cellophane 
membrane dialysis bags containing buffer solutions pH 8 at 37 Cº was studied and the 
rate of the hydrolysis was determined However, no sharp results were obtained and 
further study should be undertaken to draw conclusions on the feasibility of using these 
prodrugs in human [71]. 
In 1996, several NSAIDs such as ibuprofen, naproxen, diclofenac and ketorolac 
were reacted with R-(-)-2-amino-1-butanolwith the aim of providing the corresponding 
amide prodrugs with better bioavailability and less gastrointestinal side effects. The 
analgesic activity and toxicity of the synthesized prodrugs were investigated and 
compared to that of the corresponding active parent drugs [72]. 
In 1997, Jilani et al. have synthesized hydroxyl ethyl esters of diclofenac and 
mefenamic acid aiming to provide NSAIDs prodrugs with efficient analgesic activity 
and lesser gastrointestinal side effects than their active parent drugs. Stability study on 
those prodrugs was conducted in 1N HCl, buffer solutions of pH 7.4 and human plasma. 
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The hydrolytic degradation rate of the diclofenac ester in aqueous buffer solutions was 
very slow with a half-life of more than 22 hours, whereas the degradation rate in human 
plasma was very fast with a half-life value of less than 1.2 hours. This indicates that the 
diclofenac prodrug is quite stable in the stomach conditions and hence It is expected that 
its gastrointestinal side effects will be lesser than that of diclofenac due to masking the 
free carboxylic group in diclofenac, which is believed to be responsible in part for these 
adverse effects [57]. 
In 1999, Mahfouz et al. have conducted ulcerogenicity study, using electron 
microscopy on rat’s stomach; the rats were treated for 4 days with the synthesized 
NSAIDs ester prodrugs before the ulcerogenicity test. The study revealed that the 
synthesized prodrugs have shown lesser irritation to the stomach’s mucosa than their  
active parent drugs [73]. 
In 2000, Bandarage and coworkers synthesized diclofenac ester prodrugs containing 
a nitrosothiol (S-NO) group aiming to provide NSAIDs with the capability to donate N-
O group. These prodrugs were orally administered to mice for bioavailability and 
toxicity evaluation. The study demonstrated that those prodrugs released the active 
parent drug, diclofenac, in a significant amount within 15 minutes and showed an 
efficient inflammatory effect. The S-NO diclofenac prodrugs were shown to be much 
saferthan their active parent drug, diclofenac. In addition, the study demonstrated that 
rat stomach lesions caused by S-NO-diclofenac derivatives were less than lesions 
caused by the parent drug, diclofenac [74]. 
In 2002, Hirabayashi and coworkers have carried out a study on in vivo disposition 
at whole body, organ and cellular levels of bisphosphonic prodrug of diclofenac (DIC-
BP) upon administration of a dose in the range of 0.32-10 mg/kg. Their study indicated 
that both total body clearance and volume of distribution at steady state were reduced 
while the plasma half-life was prolonged. In addition, the study revealed that more than 
50% of DIC-BP was transported into osseous tissues when was given in a dose of up to 
1mg/kg, however when the dose was increased the skeletal distribution was decreased 
and both hepatic and splenic accumulations were increased. This is because 
bisphosphonates cannot be distributed in tissues but they can form a large complex with 
endogenous metalsin plasma and are recognized as foreign substances from 
macrophages and thus being taken by the reticuloendothelial system. In order to 
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optimize the DIC-BP prodrug’s delivery, the dosage regimen should be such that the 
plasma concentration of DIC- BP is maintained at a level lower than that required for 
precipitate complexes, similar to that of other bisphosphonates [75]. 
In 2004, Dalpiaz and coworkers have studied the in vitro intracellular uptake of 
diclofenac and its conjugate ascorbic acid (AA-Diclo) and their affinity for the SVCT2 
transporter. In addition, the AA-Diclo prodrug stability was investigated. The hydrolysis 
study followed a first-order kinetics with a half-life of about 10 hoursin plasma and 
about 3 hours in the whole blood, suggesting that AA-Diclo prodrug is a potential 
candidate to enhance the short half-life of diclofenac in vivo [76]. 
In 2004, Khan and coworkers have synthesized a number of glyceride derivatives of 
diclofenac and have studied their gastrointestinal side effects, anti-inflammatory and 
analgesic activity. In addition, the group has investigated the release of the active parent 
drug from these prodrugs in a wide range of pHs. Their results revealed that the 
synthesized glyceride prodrugs were found to lack any gastrointestinal side effects and 
their analgesic and anti-inflammatory effects were significantly greater than that of the 
active parent drug, diclofenac [77]. 
In 2009, Manon et al. have synthesized a number of diclofenac - antioxidant mutual 
prodrugs by conjugating diclofenac with different antioxidants having anti-ulcerogenic 
activity. The study screening revealed that the synthesized mutual prodrugs retained the 
anti-inflammatory activity as diclofenac, however with lesser ulcerogenic side effects 
[78]. 
In 2010, Nemmani et al. have designed, synthesized and evaluated new NO-
releasing NSAID prodrugs   such   as   NO-Aspirin   and   NO-diclofenac. NO-
diclofenac showed excellent pharmacokinetic, anti-inflammatory properties. In  
addition, this  prodrug showed significant NO-releasing  properties  and  protected  rats  
from  NSAID-induced  gastric  damage which could be attributable to the beneficial 
effects of  NO released from this prodrug [79]. 
In 2011, diclofenac ester prodrugs were synthesized and their in vitro and in vivo 
pharmacokinetic and pharmacodynamics properties were evaluated. A study which 
conducted after oral administration of ester prodrugs, revealed that these compounds 
have a very good analgesic and anti-inflammatory activity with lesser gastrointestinal 
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irritation than their active parent drug, diclofenac, and they underwent a rapid enzymatic 
hydrolysis to their parent drug[80]. 
In 2012, Santos et al. have synthesized 1-(2,6-dichlorophenyl)indolin-2-one,a 
diclofenac prodrug, and studied its therapeutic activity. The study demonstrated that the 
new prodrug has shown relevant anti-inflammatory properties without gastrointestinal 
side effects. Furthermore, the study showed that the prodrug decreased PGE2 levels, 
COX-2 expression and cellular influx into peritoneal cavity induced by carrageenan 
treatment. The pharmacokinetic studies on the prodrug have shown in vivo enzyme 
catalyzed interconversion of the prodrug to its parent active drug, diclofenac. Santos et 
al. have concluded based on this study that the synthesized new nonulcerogenic NSAID 
prodrug is useful to treat inflammatory conditions by long-term therapy [81]. 
In 2012, Ghosh et al. have synthesized four codrugs of naltrexone and diclofenac 
linked together via phenolic or alcoholic linker. Transdermal flux, permeability and skin 
concentration of both parent drugs and codrugs were quantified to form a structure 
permeability relationship. The results revealed that all codrugs underwent 
bioconversionin the skin. The extent of the bioconversion was found to be dependent on 
the structure; phenol linked codrugs were less stable compared to the secondary alcohol 
linked ones. The flux of naltrexone across microneedle treated skin and the skin 
concentration of diclofenac were higher for the phenol linked codrugs. The polyethylene 
glycol link enhanced solubility of the codrugs, which translated into flux enhancement. 
Based on the study results, Gosh et al.concluded that polyethylene glycol linked 
naltrexone diclofenac codrug is better suited for a 7 day drug delivery system both in 
terms of stability and drug delivery [82]. 
In 2014, Suryawanshi et al. have synthesized five diclofenac ester prodrugs by 
reacting the corresponding alcohol with the NSAID drug aiming at reducing the 
undesired side effects, the most important being (GI) irritation and ulceration, 
associated with the use of NSAIDs. It is widely believed that using the prodrug 
approach by temporary blocking the free carboxylic group present in the NSAIDs till 
their systemic absorption, is the best way to retain the anti-inflammatory effect of the 
NSAID and eliminate all gastrointestinal adverse effects associated with its use. All five 
diclofenac ester prodrugs were evaluated for anti-inflammatory activity by Carrageenan 
Induced Rat hand Paw method and all of the prodrugs without exception showed quite 
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appreciable anti-inflammatory activity, so the mutual prodrug will specifically and 
efficiently target the cancerous cells [83]. 
In 2014, Hasan et al. have synthesized eight diclofenac- chalcone mutual prodrugs 
aiming to provide anti-inflammatory agents with enhanced anti-inflammatory activity 
and less ulcerogenic adverse effects than their parent drugs. The mutual prodrugs were 
synthesized by conjugation of diclofenac with chalcone derivatives by the Claisen–
Schmidt condensation of acetophenone or p-hydroxy acetophenone with benzaldehyde 
or appropriately substituted benzaldehyde in the presence of a catalyst. The anti-
inflammatory activity of the synthesized fluorinated chalcone derivative was performed 
using the cotton pellet-induced granuloma in rats as a model, and found to be 
comparable to that of dexamethasone. Based on this study, Hasan et al.have concluded 
that chalcones with their pronounced anti-inflammatory activity can synergize the 
activity of diclofenac when both are in the same compound (codrug) [84]. 
2.2  Prodrugs design based on intramolecular processes 
 
The striking efficiency of enzyme catalysis has inspired many organic chemists and 
biochemists to explore enzyme mechanisms by investigating particular intramolecular 
processes such as enzyme models which proceed faster than their intermolecular 
counterparts. A novel prodrug approach of intramolecular processes (enzyme models) 
was utilized to design prodrugs which can chemically release the active parent drug in a 
controlled manner. In this approach, the design of the prodrugs is based on 
computational calculations using quantum mechanics and molecular mechanics methods  
and correlations of experimental and calculated reactions rates. The rate of the drug 
release is solely dependent on the rate limiting step for the intraconversion reaction.  
Currently, computational methods including quantum mechanics such as ab initio, a 
semi-empirical, density functional theory (DFT), and molecular mechanics are 
increasingly and widely  used as reliable tool that provide structure-energy calculations 
for  prediction the potential drugs and prodrugs [85]. 
The ab initio method is based on rigorous utilization of the Schrodinger equation and is 
restricted to small systems that do not have more than thirty atoms due to the extreme 
cost of computation time. Calculations of molecules exceeding 50 atoms can be done 
using semi-empirical methods. Density functional theory (DFT) is a semi-empirical 
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method used  to calculate geometric and energies for medium-sized systems(up to 60 
atoms) of biological and pharmaceutical interest and is not restricted to the second row 
of the periodic table [3]. 
Various intramolecular processes were studied to understand enzyme catalysis in order 
to design novel prodrug linkers. These processes include (i) proton transfer between two 
oxygen in Kirby’s acetals, and proton transfer between nitrogen and oxygen in Kirby’s 
enzyme models. (ii) intramolecular acid-catalyzed hydrolysis in Kirby’s maleamic acid 
amide derivatives[16] and (iii) proton transfer between two oxygen in rigid systems as 
investigated by Menger. 
Based on the computational calculations conducted by Karman’s group on the above 
mentioned intramolecular processes (enzyme models), it was concluded that: (i) rates 
acceleration in intramolecular processes is a result of both entropy and enthalpy effects. 
In intramolecular ring-closing reactions where enthalpic effects were predominant, 
steric effects were the driving force for the acceleration, whereas proximity orientation 
was the determining factor in proton-transfer reactions. (ii) The distance between the 
two reacting centers is the main factor in determining whether the reaction type is 
intermolecular or intramolecular. When the distance exceeded 3 Å, an intermolecular 
engagement was preferred because of the engagement with a water molecule (solvent). 
When the distance between the electrophile and nucleophile was <3 Å, an 
intramolecular reaction was dominant. (iii)The efficiency of proton transfer between 
two oxygen and between nitrogen and oxygen in Kirby’s enzyme models is attributed to 
relatively strong hydrogen bonding in the products and the transition states leading to 
them [3]. 
Modern computational approach was utilized for the design of innovative prodrugs. During 
the past seven years, mechanisms of intramolecular processes for a number of enzyme 
models have been studied by Karaman's group and were used to design novel prodrug 
linkers. Among the enzyme models have been investigated: proton transfer between two 
oxygens and proton transfer between oxygen and nitrogen in Kirby's acetals [86] 
Karaman's group successfully designed and synthesized several novel prodrugs. 
Examples of these prodrugs include: the anti-Parkinson’s agent dopamine [87], anti-viral 
agent acyclovir [88], anti-malarial agent atovaquone [89], antihypertensive atenolol [90], 
antibacterial cefuroxime [91]and the anti-psoriasis monomethyl maleate [92]. 
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2.2.1 Design of mefenamic and diclofenac prodrugs  using Kirby`s enzyme model 
(Proton transfer in N-alkylmaleamic acids) 
 
The design of mefenamic and diclofenac  prodrugs was accomplished using Kirby’s 
enzyme model that describes proton transfer reactions in N-alkylmaleamic acids [92] 
(Figure2.1). The DFT calculations run on these systems revealed that the hydrolysis 
reaction occurs via an intramolecular general acid catalysis mechanism and the reaction 
rate is dependent on the following factors: (1)The difference between the strain energies 
of intermediate and product and intermediate and reactant. (2)The distance between the 
two reacting centers. (3)The attack angle. Further, a linear correlation between the 
calculated proton transfer reaction and the experimental rates established the credibility 
of using DFT methods in predicting energies and rates for proton transfer reactions    
[86, 93]. 
 
Figure ‎2.1:  Acid-catalyzed hydrolysis of N-alkylmaleamic acids 
 
The calculations also demonstrated that the acid catalyzed reaction involves three steps: 
(1) proton transfer from the carboxylic group to the adjacent amide carbonyl oxygen,(2) 
nucleophilic attack of the carboxylate anion onto the protonated carbonyl carbon and (3) 
dissociation of the tetrahedral intermediate to provide products. 
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Figure ‎2.2: Proposed mechanism for the acid-catalyzed hydrolysis of N-alkylmaleamic 
acids. 
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Chapter Three 
3. Experimental Part 
3.1  Materials 
 
All organic salts were of analytical grade and were used without further purification. 
Organic buffer components were distilled or recrystallized. Distilled water was 
redistilled twice before use. Dimethylamine, triethylamine, anhydrous sodium 
dihydrogen phosphate, oxalyl chloride, diclofenac sodium and diclofenac potassium,   
tranexamic acid,and mefenamic acid were commercially obtained from Sigma Aldrich. 
Methanol, acetonitrile and water for analysis were for HPLC grade and were purchased 
from Sigma Aldrich. High purity chloroform, tetrahydrfuran (THF), dichloromethane, 
hexane, ethylacetate, dimethylformamide, and diethyl ether (> 99%) were purchased 
from Biolab (Israel).  
3.2 Instrumentation 
 
HPLC measurements were carried out using Shimadzu prominence high performance 
liquid chromatography system HPLC-PDA, (Shimadzu corp. Japan). LC-Esi-MS 
measurements were performed employing an agilent 1200  series liquid chromatography 
coupled with a 6520 accurate mass quadruple time of flight mass spectrometer (Q-TOF 
LC/MS)The high pressure liquid chromatography system consisted of a model 2695 
HPLC from Waters (Israel) equipped with a Waters 2996 Photodiode array. Data 
acquisition and control were carried out using Empower ™ software (Waters: Israel). 
Analytes were separated on a 4.6 mm x150 mm C18 XBridge® column (5 μm particle 
size) used in conjunction with a 4.6 mm, 20 μm, XBridge® C18 guard column. 
Microfilters 0.45μm porosity were normally used (Acrodisc® GHP, Waters). pH meter 
model HM-30G: TOA electronics™ was used in this study to measure the pH value for 
the buffers. UV-Spectrophotometer the concentrations of samples were determined 
spectrophotometrically (UV-spectrophotometer, Model: UV-1601, Shimadzu, Japan) by 
monitoring the absorbance at λmax for each drug. Centrifuge: Labofuge
®
200 Centrifuge 
was used, 230 V 50/60 Hz. CAT. No.  284811. Made in Germany. 
1
H-NMR: Data were 
collected using Varian Unity Inova400 MHz spectrometer equipped with a 5-mm 
switchable and data were processed using the VNMR software. For 
1
H-NMR, chemical 
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shifts are reported in parts per million (ppm, δ) downfield from tetramethylsilane 
(TMS). Spin multiplicities are described as s (singlet), brs (broad singlet), t (triplet), q 
(quartet), and m (multiplet). All infrared spectra (FTIR) were obtained from a KBr 
matrix (4000–400 cm-1) using a PerkinElmer Precisely, Spectrum 100, FT-IR 
spectrometer. 
3.3 Synthesis of the Prodrugs 
3.3.1 Mefenamic dimethylamine (Scheme 1) 
First step: synthesis of mefenamic acyl chloride 
In a 250 ml round-bottom flask, 1 equivalent of of mefenamic acid (4.28gm, 20 mmol) 
was dissolved in anhydrous dichloromethane (50 ml), then 2 equivalents of  of oxalyl 
chloride(40 mmol, 3.4 ml) was added and 0.5 ml of DMF was slowly added as a 
catalyst, the resulting solution was stirred at room temperature overnight, then the 
solvent and excess oxalyl chloride were removed under reduced pressure. 
Second step: mefenamic acyl chloride–dimethylamine reaction 
 Product from step 1) was dissolved in 40ml dried dichloromethane. 1 equivalent of 
dimethylamine (5 ml ) was added to the reaction. The mixture was allowed to stir 
overnight at room temperature until the reaction was completed. The progress of the 
reaction was monitored by TLC. After completion of the reaction 50 ml 
dichloromethane was added to the reaction mixture. The reaction mixture was 
transferred to a separatory funnel and the organic layer was extracted with 100ml 1N 
NaOH then with 100ml 1N HCl. The organic layer was collected and washed with 100 
ml water. Sodium sulfate was added to dry excess water followed by filtration. The 
solution was evaporated under vacuum to furnish the crude product which was purified 
by column chromatography. The yellow precipitate formed was collected and dried (3.8 
gm) with yield of (88.7%) and m.p (300C
o
). 
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Scheme 1: Synthesis of mefenamic dimethylamine  
3.3.2 Diclofenac benzyl (Scheme 2) 
In a 250 ml round-bottom flask 1 equivalent of diclofenac potassium (3.43gm,20mmol) 
was dissolved in 100ml dioxane, 2 gm of sodium carbonate was added, the resulting 
solution was stirred for 30 minutes. Then, 4 equivalents  of benzyl bromide (5ml, 
80mmol) was added to reaction mixture. The reaction was allowed to heat until reflux 
for 3 days until the reaction was completed. The progress of the reaction was monitored 
by TLC. After completion of the reaction, the mixture was filtered and washed with 
dioxane. The filtrate was evaporated under vacuum to furnish a product which was 
purified by column chromatography. The white precipitate formed was collected and 
dried (3 gm) with yield (87.4%), m.p (300C
o
) 
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Scheme 2: Synthesis of diclofenac benzyl  
 
3.3.3 Mefenamic-tranexamic (Scheme 3) 
 
First step: synthesis of mefenamic acyl chloride 
 
In a 250 ml round-bottom flask, 1 equivalent of of mefenamic acid 4.28 gm (20 mmol) 
was dissolved in anhydrous dichloromethane (50 ml), then  2 equivalents of of oxalyl 
chloride (3.4 ml,40mmol ) and 0.5 ml of DMF were slowly added, the resulting solution 
was stirred at room temperature overnight, then the solvent and excess oxalyl chloride 
were removed under reduced pressure. 
Second step: reaction of mefenamic acyl chloride with tranexamic acid 
In a 250 ml round-bottom flask mefenamic chloride (product from step 1) was dissolved 
in dichloromethane (30 ml), a solution of 1 equivalents tranexamic acid(3.14 g,20mmol) 
in dry DMF (20ml) and 5ml triethylamine were added, the resulting solution was stirred 
for 3 days at room temperature until the reaction was completed. The progress of the 
reaction was monitored by TLC. The organic layer was extracted with 100 ml 1N HCl, 
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the organic layer was dried over MgSO4 anhydrous, filtered and evaporated to dryness. 
The product was a yellow precipitate (4gm) with a yield of 93% , and m.p over 300C
o
.  
 
H3C
H3C
HN
O
HO
1)Dichloromethane
2)oxalylchloride
3)DMF
H3C CH3
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Mol. Wt.: 380.48
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H3C
H3C
HN
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Scheme 3: Synthesis of mefenamic tranexamic 
 
3.3.4 Diclofenac tranexamic (Scheme 4) 
First step : diclofenac protonation 
In a 250 ml round-bottom flask, 1 equivalent of diclofenac potassium (6.68 gm ,20 
mmol) was dissolved in 30 ml methanol, then 3-4 equivalents  of concentrated HCl (4ml) was 
added. The mixture was allowed to stir at room temperature overnight. The reaction solvent was 
removed under reduced pressure and the residue was dissolved in THF (50 ml), filtered and 
evaporated. 
Second step: synthesis of diclofenac acyl chloride 
In a 250 ml round-bottom flask, 1 equivalent of the protonated diclofenac (product from 
step 1) (20 mmol) was dissolved in anhydrous dichloromethane (50 ml), 2 equivalents 
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of oxalyl chloride(3.4 ml) and 0.5 ml of DMF were slowly added, the resulting solution 
was stirred at room temperature overnight, then the solvent and excess oxalyl chloride 
were removed under reduced pressure. 
 
Third step: reaction of diclofenac acyl chloride with tranexamic acid 
In a 250 ml round-bottom flask diclofenac chloride (product from step 2) was dissolved 
in dichloromethane (30 ml), a solution of  1 equivalent of tranexamic acid 3.14 g in dry 
DMF (20ml) and 5ml triethylamine was added, the resulting solution was stirred for 3 
days at room temperature until the reaction was completed. The progress of the reaction 
was monitored by TLC. After completion of the reaction, the organic layer was 
extracted with 100 ml 1N HCl. The combined organic layer was dried over MgSO4 
anhydrous, filtered and evaporated to dryness. The product was a white precipitate(5.5 
gm) with a yield of  83% and m.p (100C
o
) 
Cl
Cl
NH
O
O-K+
Cl
Cl
NH
O
OH
Cl
Cl
NH
O
Cl
Cl
Cl
NH
O
NH
HOOC
CH2
1)MeOH
2) HCl
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2)Oxalyl chloride
3)DMF
1)DCM
2)Triethylamine
COOH
H2N
4-({2-[2-(2,6-Dichloro-phenylamino)-phenyl]-acetylamino}-
methyl)-cyclohexanecarboxylic acid
C22H24Cl2N2O3
Mol. Wt.: 435.34
 
Scheme 4: Synthesis of diclofenac tranexamic. 
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3.4 Chemical hydrolysis 
Acid catalyzed hydrolysis of diclofenac and mefenamic prodrugs and codrugs were 
carried out in aqueous buffers in the same manner to that executed by Kirby et al. on 
maleamic acids [94]. This is to investigate whether the prodrugs or codrug undergoes 
hydrolysis in aqueous medium and to what extent or not, suggesting the fate of the 
prodrugs or codrug in the system. The synthesized prodrugs and codrugs were studied 
using  high performance liquid chromatography (HPLC) at constant temperature (37 
o
C) 
and at ambient pressure in different buffers  1N HCl, pH 2.5 (stomach), pH 5.5 
(intestine) and pH 7.4 (blood) which correspond to the physiological environments in 
the human body. 
 
3.4.1 Buffer Preparation 
 
Potassium dihydrogen phosphate(6.8 g) were dissolve in 900 ml water for HPLC, the 
pH of buffers pH 2.5  was adjusted by diluted  o- phosphoric acid and water was added 
to a final volume of 1000 ml (0.05M). The same procedure was done for the preparation 
of buffers pH 5.5 and pH7.4, however, the required pH was adjusted using 1 N NaOH. 
Intraconversion of 500 ppm mefenamic acid dimethylamine and diclofenac solutions, in 
1N HCl, buffer pH 2.5, buffer pH 5.5 or buffer pH 7.4, to its parent drug was monitored 
by HPLC at a wavelength of 254 nm. Conversion reactions were run mostly at 37.0 ˚C. 
Intra-conversion of 500 ppm mefenamic tranexamic, diclofenac tranexamic solutions, in 
1N HCl, buffer pH 2.5, buffer pH 5.5 and buffer pH 7.4, to its parent drug were 
monitored by HPLC at a wavelength of 254 nm. Conversion reactions were run mostly 
at 37.0 ˚C. 
3.4.2 Calibration curve 
A 100 ml stock solution of mefenamic dimethylamine and diclofenac benzyl  with a 
final concentration of 500 ppm were prepared by dissolving 50 mg from each prodrug in 
100 ml methanol. The following diluted solutions were prepared from the stock 
solution: 100, 200, 300 and 400 ppm. Each solution was then injected to the HPLC 
apparatus using 4.6 mm x 250 mm, 5 µm C18 XBridge ® column, mobile phase 
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contains water: acetonitrile (25:75) a flow rate of 1 ml min
-1
 and UV detection at a 
wavelength of 254 nm. 
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R
2 
of the 
plot was recorded. 
A 100 ml stock solution of mefenamic tranexamic and diclofenac tranexamic  with a 
final concentration of 500 ppm were prepared by dissolving 50 mg from each codrug in 
100 ml methanol. The following diluted solutions were prepared from the stock 
solution: 100, 200, 300 and 400 ppm. Each solution was then injected to the HPLC 
apparatus using 4.6 mm x 250 mm, 5 µm C18 XBridge ® column, mobile phase for 
mefenamic tranexamic water: acetonitrile (10:90) and (75:25) for diclofenac 
tranexamic, a flow rate of 1 ml min
-1
 and UV detection at a wavelength of 254 nm. 
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R
2 
of the 
plot was recorded. 
 
3.4.3 Preparation of standard and sample solution 
A 500 ppm of standard (mefenamic acid, diclofenac potassium) were prepared by 
dissolving 50 mg of each drug (mefenamic acid, diclofenac) in 100 ml of 1N HCl, 
buffer pH 2.5, buffer pH 5.5 or buffer pH 7.4, then each sample was injected into HPLC 
to detect the retention time of mefenamic. 
A 500 ppm of standard linker (dimethylamine and benzyl bromide) was prepared by 
dissolving 50 mg of each linker in 100 ml of 1N HCl, buffer pH 2.5, buffer pH 5.5 or 
buffer pH 7.4, then each sample was injected into HPLC to determine the retention time 
of linker. 
A 500 ppm of each prodrug was prepared by dissolving 50 mg of each prodrugin 100 ml 
of 1N HCl, buffer pH 2.5, buffer pH 5.5 or buffer pH 7.4 then each sample was injected 
into the HPLC to determine the retention time. 
The reaction progress was followed by monitoring the disappearance of the prodrug and 
appearance of the drug and linker versus time. 
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Results and discussion 
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Chapter Four 
4. Results and Discussion 
4.1 Characterization 
 
Mefenamic acid and mefenamic dimethylamine were characterized by FT-IR, LC-MS 
and 
1
H-NMR spectroscopy. 
 
Mefenamic acid , IR spectrum (Figure 4.1)  shows an absorbance  at 1653 cm
-1
 
corresponds to C=O of carboxylic acid and 3312 cm
-1
corresponds to N-H.                                                 
1
H-NMR (Figure 4.2)   δ (ppm) CD3OD:2.16 (s, 3H, Ar-(CH3)) , 2.35 (s , 3H, Ar-(CH3) 
, 6.63(t, 1H, Ar-H), 7.01(d, 2H, J=6.7 ,Ar-H), 7.11(t, 1H, Ar-H), 7.23(t, 1H, Ar-H), 7.94 
(d, 2H,  J=1.65, Ar-H). 
 
 
Figure ‎4.1: FT-IR spectrum of mefenamic acid. 
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Figure ‎4.2: 1H-NMR spectrum of mefenamic acid. 
 Mefenamic dimethylamine.  
M.P: 300 C
o 
 H
1
NMR: in (Acetone-d6, ppm): 2.45(s, 3H, Ar-(CH3)), 2.49(s, 3H, Ar-(CH3)), 2.76(S, 
6H, N-(CH3)), 2.80 (s, 6H, N-(CH3)), 7.10(d, J=7.12, 2H, Ar-H), 7.23 (t, 1H, Ar-H), 
7.66 (t, 1H, Ar-H), 7.74 (t, 1H, Ar-H), 8.12(d, 1H,Ar-H), 8.29(d, J=1.08, 2H, Ar-H) 
IR (KBr/νmax cm
–1
) 1614 (C=O), 2963 (N-H ), m/z (M+1)+269.1648 
The IR spectrum (Figure 4.3)  shows an additional signals at frequencies of1712 cm
-1
, 
1643 cm
-1
correspond to C=O of the amide. A high resolution LC-MS (Figure4.4) shows 
a protonated peak at m/z 269.1648(M+1)
+
 The 
1
H-NMR (Figure4.5) dimethylamine 
proton show singlet peaks at 2.76and 2.80 ppm. 
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Figure ‎4.3 : FT-IR spectrum of  mefenamic dimethylamine. 
 
 
 
 
Figure ‎4.4: LC-MS spectrum of mefenamic  dimethylamine. 
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Figure ‎4.5: 1H-NMR spectrum of mefenamic  dimethylamine. 
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Diclofenac: The IR spectrum (Figure 4.6) shows an absorbance at 1578                        
cm
-1
corresponds to C=O. The H
1
NMR (Figure 4.7): 400MHz (CDCl3, ppm): 3.63 (s, 
2H, COCH2) , 6.35 (d, 1H, J= 0.8, Ar-H),6.80 (t , 2H, Ar-H), 6.98 (t, 1H, Ar-H), 7.20(d, 
1H , J=1.2 , Ar-H), 7.35(d,2H, J=3.6 , Ar-H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.6 FT-IR spectrum of diclofenac potassium. 
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Figure ‎4.7: 1H-NMR spectrum of diclofenac. 
 
Diclofenac benzyl.  
M.P: 300 C
o
. 
1
H-NMR (CDCl3, ppm): 3.86 (s,2H,COCH2) , 5.18 (s, 2H, CH2-Ar) , 6.54(d, 1H, J= 8, 
Ar-H),6.88 (d, 2H, J= 21.6, CH2-Ar-H),6.97 (t, 1H, Ar-H), 7.14(t, H, Ar-H), 7.24(d, 1H, 
J=1.6 ,Ar-H),7.31 (d, 1H, J= 3.2, Ar-H), 7.37(t, 5H, Ar-H).  
IR (KBr/νmax cm
–1
) 1743(C=O), 3361(N-H).m/z 386.07(M+1)
+
. 
IR spectrum(Figure 4.8) shows an additional signals with frequencies of 1743 cm
-1
,3361 
cm
-1 
correspond to carbonyl group (C=O) and (N-H), respectively. A high resolution 
LC-MS (Figure 4.9) shows a protonated peak at m/z 386.07(M+1)
+
.The 
1
H-NMR 
(Figure 4.10)shows additional singlet peak at 5.18ppm and doublet and triplet peaks at 
6.30- 7.32 corresponding to the  protons of the benzyl moiety.   
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Figure ‎4.8:  FT-IR spectrum of diclofenac benzyl. 
 
 
 
Figure ‎4.9. LC- MS spectrum of diclofenac benzyl. 
Operator 914
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Description
4000 5003500 3000 2500 2000 1500 1000
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Figure ‎4.10: 1H-NMR spectrum of diclofenac benzyl. 
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Tranexamic acid. The IR spectrum (Figure 4.11) shows an absorbance at 1642 cm
-1
 
corresponds to C=O. A high resolution LC-MS (Figure 4.12) at the ESI (positive mode) 
shows a protonated peak at m/z 158.1176 (M+1)
+
, an adduct of [M
+
Na]
+
 appeared at m/z 
of 180.0993. The 
1
H-NMR (Figure 4.13) peaks occur at  1.06 ppm (q, 2H, CH-CH2-
CH2), 1.40 ppm (q, 2H, CH-CH2-CH2), 1.54 ppm (m, 1H, CH2-CH-CH2-CH2), 1.84 
ppm (m, 2H, CH2-CH2-CH ), 2.02 ppm (m, 2H, CH2-CH2-CH), 2.22 ppm (m, 1H, CH2-
CH-CH2-CH2), 3.17 ppm (d, 2H, CH2-N). 
 
 
Figure ‎4.11: FT-IR spectrum of tranexamic acid. 
 
 
Figure ‎4.12:  LC-MS spectrum of tranexamic acid. 
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Figure ‎4.13: 1H-NMR spectrum of tranexamic acid. 
Mefenamic tranexamic. 
M.P  over 300 °C 
1
H-NMR (CDCl3) 0.88 (m, 1H, cyclohexane-H), 1.12( q, 8H, cyclohexane-H), 1.14 (m, 
1H, cyclohexane-H),  1.54(s, 6H, Ar-(CH3)2 ), 2.46 (d, 2H, J=10.8, NH(CH2), 
7.11(d,1H, J=8.4 ,Ar-H), 7.63(t, 2H, Ar-H), 7.67 (d, 2H, J=1.6, Ar-H), 8.2 (d, 2H, J=8.4, 
Ar-H). 
IR (KBr/νmax cm
–1
)1653 (C=O), 3312(N-H) 
.m/z386.07(M+1)
+
. 
IR spectrum (Figure4.14) shows an additional peaks with frequencies of1623 cm
-
1
(C=O) and 3266 cm
-1
(N-H). A high resolution LC-MS (Figure4.15) shows a protonated 
peak at m/z 381.3227(M+1)
+
. The 
1
H-NMR (Figure4.16) shows additional doublet 
peakat 2.46 ppm with coupling constant of 10.8 Hz and multiplet at 0.88-1.14 ppm 
correspond to the cyclohexyl ring of the tranexamic acid moiety. 
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Figure ‎4.14:  FT-IR spectrum of mefenamic tranexamic 
 
 
Figure ‎4.15  LC-MS spectrum of mefenamic tranexamic. 
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Figure ‎4.16: 1H-NMR spectrum of mefenamic tranexamic. 
 
Diclofenac tranexamic.  
M.P: 100C
o 
H
1
NMR  (CDCl3, ppm): 3.75 (s, 2H, COCH2), 3.82(d , 2H, CH2-cyclohexane),  6.54(d, 
1H, J=0.8, Ar-H), 6.97 (t,  2H , Ar-H), 7.14 (t, 2H, Ar-H), 7.22 (d, H, Ar-H), 7.24(d, 
2H, J=1.6 , Ar-H). 
FTIR: ( KBr,cm
-1
)  in diclofenac tranexamic  1738(C=O), 3353(NH) 
m/z 435.1160 [M+1]
+ 
IR spectrum (Figure4.17) shows additional two peaks at1738(C=O) and 3353(NH). A 
high resolution LC-MS (Figure4.18) shows a protonated peak at m/z 435.1160(M+1)
+
. 
The 
1
H-NMR (Figure 4.19) shows an additional doublet peak at 3.82 ppm corresponds 
to the protons of the methyl groups of the tranexamic acid moiety. 
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Figure ‎4.17: FT-IR spectrum of  diclofenac tranexamic 
 
 
Figure ‎4.18 LC-MS spectrum of diclofenac tranexamic. 
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Figure ‎4.19: 1H-NMR spectrum of diclofenac tranexamic. 
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4.2 Calibration curves 
Calibration curves were obtained by plotting the peak area versus concentration as 
displayed in Figure (4.20) for mefenamic dimethylamine, diclofenac benzyl ,mefenamic 
tranexamic and and diclofenac benzyl. As shown in the figure, excellent linearity with 
correlation coefficient (R
2
) above 0.95was obtained. 
 
Figure ‎4.20: Calibration curves for mefenamic dimethylamine, diclofenac benzyl 
,mefenamic tranexamic and and diclofenac tranexamic. 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
4.3      Kinetic studies 
 
4.3.1 Mefenamic dimethylamine and diclofenac benzyl  
4.3.1.1 Mefenamic dimethyl amine 
 
Mefenamic dimethyl amine was hydrolyzed in 1N HCl to release the corresponding 
parent drug within 10 hrs,  the reaction displayed strict first order kinetics as the kobs was 
fairly constant and a straight plot was obtained on plotting log concentration of residual 
prodrug vs. time. The rate constant (kobs) and the corresponding half-lives (t1/2) for these 
prodrugs were calculated from the linear regression equation correlating the log 
concentration of the residual prodrug vs. time figure (4.21). On the other hand, at pH 
2.5, pH 5.5 and pH 7.4, mefenamic dimethylamine was entirely stable and no release of 
the parent drug was observed. This is due to the fact that mefenamic dimethylamine 
undergoes acid-catalyzed hydrolysis (intramolecular process), where the proton is 
transferred from the nitrogen of mefenamic moiety to the carbonyl of the amide 
followed by cyclization and dimethylamine departure. This reaction occurs at low pH 
where the nitrogen of mefenamic acid can accept a proton. In higher pHs the mefenamic 
acid moiety cannot be protonated and therefore, no intramolecular proton transfer is 
occurred.Kinetic data is listed in Table 1. 
 
Table1 : The observed k value and t1/2 for the intraconverion of Mefenamic 
dimethylamine in 1N HCl and at pH 2.5 , pH 5.5 and pH 7.4. 
 
Medium  kobs (h
-1
)  t½ (h)  
1N HCl  6.909*10
-2 
10 
Buffer pH 2.5  No reaction  No reaction  
Buffer pH 5.5  No reaction  No reaction  
Buffer pH 7.4  No reaction  No reaction  
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Figure ‎4.21: First order hydrolysis plot for the intraconverion of Mefenamic 
dimethylamine in  1N HCl. 
Figure ‎4.22:Chromatogram of  mefenamic acid , Rt=2.5min 
 
 
Figure ‎4.23: Chromatogram mefenamic-dimethylamine Rt=3.6min 
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Figure ‎4.24 : Chromatograms showing the intra-conversion of mefenamic 
dimethylamine at  1 NHCl (a) at zero time, (b) after 30 hours. 
 
4.3.1.2 Diclofenac benzyl  
Diclofenac benzyl was hydrolyzed in 1N HCl and pH 7.4 to release the corresponding 
parent drug within 4 hrs and 1 hrs respectively (Table 2). The reaction displayed strict 
first order kinetics as the kobs was fairly constant and a straight plot was obtained on 
plotting log concentration of residual prodrug vs. time. The rate constant (kobs) and the 
corresponding half-lives (t1/2) for these prodrugs were calculated from the linear 
regression equation correlating the log concentration of the residual prodrug vs. time 
figure(4.25). At pH 2.5, pH 5.5 diclofenac benzyl was entirely stable and no release of 
the parent drug was observed. This is due to the fact that diclofenac-benzyl is an ester. 
Generally esters are hydrolyzed in strong acidic or basic media. Therefore, it is expected 
that at pH 1 or less (very acidic condition) or pH 7.4 (a relatively basic condition, where 
the nitrogen of diclofenac is not protonated) the ester will undergo hydrolysis to give 
diclofenac and benzyl alcohol. pHs of 2.5 and 5.5 are not sufficient basic medium for 
providing OH- as a nucleophile needed to attack the ester carbonyl for the hydrolysis to 
occur. At low pH (1N HCl or pH less than 1) the hydrolysis reaction is acid-catalyzed 
hydrolysis, whereas, at pH 7.4 the hydrolysis reaction is base-catalyzed hydrolysis. 
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Table 2 : The observed k value and  t1/2 for the  intraconverion of diclofenac benzyl in  
1N HCl and at pH 2.5 , pH 5.5 and pH 7.4. 
Medium kobs (h
-1
) t½ (h) 
1N HCl 17.27*10
-2
 4 
Buffer pH 2.5 No reaction No reaction 
Buffer pH 5.5 No reaction No reaction 
Buffer pH 7.4 66.78*10
-2
 1 
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Figure ‎4.25: First order hydrolysis plot for the intraconverion of diclofenac benzyl in      
a) 1NHCl , b) pH 7.4. 
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Figure ‎4.26: Chromatogram of diclofenac  Rt=2.5min 
                                    
 
Figure ‎4.27: Chromatogram of diclofenac benzyl ,Rt=5.9 
 
Figure ‎4.28: Chromatograms showing the intra-conversion of diclofenac benzyl at         
1 NHCl (a) at zero time, (b) after 24 hours. 
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Figure ‎4.29: Chromatograms showing the intra-conversion of diclofenac benzyl at                                                      
pH=7.4 (a) at zero time, (b) after 24 hours. 
 
4.2.1 Mefenamic tranexamic  and diclofenac tranexamic  
 
Under the experimental conditions, mefenamic tranexamic and diclofenac tranexamic 
hydrolyzed to release the parent drugs as evident by HPLC analysis. At constant pH and 
temperature, the reaction displayed strict first order kinetics as the kobs was fairly 
constant and a straight plot was obtained on plotting log concentration of residual 
codrug vs. time. The rate constant (kobs) and the corresponding half-lives (t1/2) 
mefenamic tranexamic and diclofenac tranexamic in the different media were calculated 
from the linear regression equation correlating the log concentration of the residual 
codrug vs. time. It is worth noting that 1N HCl and pH 2.5 were selected to examine the 
intraconversion of mefenamic tranexamic and diclofenac tranexamic in the pH as of 
stomach, since the mean fasting stomach pH of adult is approximately 1-2.5. 
Furthermore, environment of buffer pH 5.5 mimics that of beginning small intestine 
route, whereas pH 7.4 was selected to determine the intraconversion of the tested 
prodrugs in blood circulation system. Acid-catalyzed hydrolysis of mefenamic 
tranexamic and diclofenac tranexamic was found to be much higher in 1N HCl than at 
pH 2.5, pH 5.5and pH 7.4. Mefenamic tranexamic in 1NHCl was hydrolyzed to release the 
parent drugs nearly in one hour while the t1/2 value of diclofenac tranexamic in 1 NHCl 
was about 30 hrs. On the other hand, at pH 2.5, pH 5.5 and pH 7.4, both codrugs were 
entirely stable and no release of the parent drugs was observed. Since the pKavalues of 
tranexamic acid is in the range of 3-4, it is expected that at pH 5.5 and 7.4 the anionic 
form of the codrugs will be dominant and the percentage of the free acid form that 
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undergoes the acid-catalyzed hydrolysis will be negligible. The discrepancy in 
hydrolysis rate between mefenamic tranexamic and diclofenac tranexamic at 1NHCl is 
attributed to the effect of the distance between the two reacting centers. It is worth noting 
that previous DFT calculations and experimental data on the acid catalyzed hydrolysis 
revealed that the efficiency of the intramolecular acid-catalyzed hydrolysis by the 
carboxyl group is remarkably sensitive to the distance between the electrophile and 
nucleophile. Systems having short distance between the two reacting centers experience 
low rates and vice versa. The kinetic data for mefenamic tranexamic and diclofenac 
tranexamic are listed in Tables 3 and 4. 
Table 1:The observed k value and t1/2 for the intraconverion of mefenamic tranexamic 
acid  in 1N HCl, pH 2, pH 5.5 and pH 7.4. 
Medium kobs (h
-1
)  t½ (h)  
1N HCl  63.6*10
-2
 1 
Buffer pH 2.5  No reaction  No reaction  
Buffer pH 5.5  No reaction  No reaction  
Buffer pH 7.4  No reaction  No reaction  
 
Table 4:The observed k value and t1/2 for the intraconverion of diclofenac tranexamic 
acid  in 1N HCl, pH 2, pH 5.5 and pH 7.4. 
 
Medium  kobs (h
-1
)  t½ (h)  
1N HCl  2. 303*10
-2
 30 
Buffer pH 2.5  No reaction  No reaction  
Buffer pH 5.5  No reaction  No reaction  
Buffer pH 7.4  No reaction  No reaction  
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Figure ‎4.30: First order hydrolysis plot for the intraconverion of mefenamic tranexamic   
in  1N HCl 
 
 
 
Figure ‎4.31: First order hydrolysis plot for the intraconverion of diclofenac tranexamic  
in  1N HCl 
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Figure ‎4.32: Chromatogram of mefenamic  Rt=4.4min 
 
 
Figure ‎4.33: Chromatogram of mefenamic tranexamic  Rt = 3.9min 
 
 
Figure ‎4.34: Chromatograms showing the intra-conversion of  mefenamic tranexamic  
in 1NHCl at a) zero time  b) after 3 hrs 
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Figure ‎4.35: Chromatogram of diclofenac  Rt=8.6min 
 
 
Figure ‎4.36: Chromatogram of diclofenac tranexamic  Rt=12.6 min 
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Figure ‎4.37: Chromatograms showing the intraconversion of diclofenac tranexamic in 
1NHCl at a) zero time  b) after 60 hrs. 
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5. Conclusion 
 
Novel prodrugs and codrugs of mefenamic acid and diclofenac were synthesized and 
their in vitro pharmacokinetic properties were evaluated. The designed linkers by 
Karaman's group were used to mask the bitter taste and GI toxic effects of NSAIDs. 
Based on Kirby's enzyme model the synthesized prodrugs were hydrolyzed to release 
the parent drugs via intramolecular acid catalyzed hydrolysis.  
The predicted t1/2 and kobs of mefenamic dimethylamine, diclofenac benzyl, mefenamic 
tranexamic and diclofenac tranexamic were computationally calculated. It should be 
emphasized that the t1/2 of prodrugs will be determined on two major factors: (1) the pH 
of the medium and (2) the chemical structure of the linker (promoiety). Kinetic studies 
revealed that the synthesized prodrugs and codrugs exist as a free carboxylic acid form 
in the low pHs such as the stomach, whereas in the blood circulation system (pH = 7.4), 
the carboxylate anion is the predominant form. Therefore, the interconversion rates of 
NSAIDs prodrugs to NSAIDs can be programmed according to the nature of the 
prodrug linker. 
Based on Kirby`s enzyme model novel prodrugs and codrugs of mefenamic acid and 
diclofenac were synthesized and their in vitro pharmacokinetic properties were 
evaluated. The designed linkers by Karaman's group were used to mask the bitter taste, 
GI toxic effects and have the potential to release the parent drugs via intramolecular 
reaction without the need for enzyme catalysis. The rate of intramolecular acid 
catalyzed hydrolysis is dependent on the following factors:(1) the difference between 
the strain energies of intermediate and product and intermediate and reactant, (2) the 
distance between the two reacting centers and (3) the attack angle. Thus, the rate by which 
the pro-drug releases the anti-inflammatory drug can be determined according to the nature of 
the linker (Kirby’s enzyme model) 
The experimental t 1/2 value for mefenamic dimethylamine in 1NHCl was found to be 10 
hrs, while at pH 2.5, pH 5.5 and pH 7.4 the prodrug showed complete stability. 
Mefenamic dimethylamine undergoes acid-catalyzed hydrolysis (intramolecular 
process) at low pH where the nitrogen of mefenamic acid can accept a proton. In higher 
pHs the mefenamic acid moiety cannot be protonated and therefore, no intramolecular 
proton transfer can occur. Diclofenac benzyl was hydrolyzed to release the parent drug 
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within 4 and 1 hrs at 1 NHCl and pH 7.4, respectively. On the other hand, no hydrolysis 
was observed at pH 2.5 and pH 5.5. The lack of the hydrolysis at pH these two pHs 
might be due to the fact that ester hydrolysis is catalyzed by an acid or a base and the 
media of the mentioned two pHs are not sufficiently acidic nor basic to catalyze the 
ester (diclofenac benzyl) hydrolysis.  
Mefenamic tranexamic  in 1NHCl was hydrolyzed to release the parent drugs within one 
hour while the t1/2 value of diclofenac tranexamic in 1 N HCl was about 30 hrs. On the 
other hand, at pH 2.5, pH 5.5 and pH 7.4, both codrugs were entirely stable and no 
release of the parent drugs was observed. 
The discrepancy in hydrolysis rate between mefenamic tranexamic  and diclofenac 
tranexamic at  1 N HCl is attributed to the fact that in mefenamic tranexamic there is a 
possibility of intramolecular acid-catalyzed hydrolysis which stems from the short distance 
between the two reacting centers (the proton and the nitrogen of the mefenamic acid moiety), 
whereas in diclofenac tranexamic the hydrolysis is occur via intermolecular acid-
catalyzed hydrolysis due to the long distance between the proton and the nitrogen of the 
diclofenac moiety.  
In vitro binding test to bitter taste receptors for mefenamic dimethylamine, diclofenac 
benzyl , mefenamic tranexamic  and diclofenac tranexamic were found to be bitterless. 
This suggests that NSAIDs prodrugs and codrugs can replace their parent drugs for the 
use as safe and bitterless anti-inflammatory drugs for geriatrics and pediatrics. 
The ability of NSAIDs prodrugs and codrugs to reduce ulcerogenic side effects while 
retaining the anti-inflammatory events when administered makes this class of 
compounds promising new anti-inflammatory agents that should be further investigated 
and developed for future therapeutic use.  
In the next decades, it is expected that the prodrug approach will become an integral 
part of the drug discovery processes and not as a hindsight approach to the solution of 
problems associated with older drugs. 
6. Future directions: 
1- In vivo pharmacokinetic studies will be conducted in order to determine the 
bioavailability and the duration of action of the tested prodrugs.  
2- In vitro and in vivo studies will be done to determine the anti-inflammatory and 
anti-bleeding effects of the synthesized prodrugs and codrugs. 
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الاولٍت والوشخزمت الوفٍذة هواصفاث وحقٍٍن الادوٌت الوساعذة حصٌٍع ودراست 
  لذٌنلوفٌٍاك و حوض الوٍفٌٍاهٍل ل
 :الولخص
 خلفٍت:ال
أٛاع‏ِضاداخ‏الاٌرٙاب‏اٌلاسريشٚيذيح‏٘ي‏ِٓ‏تيٓ‏الادٚيح‏الأوثش‏اسرخذاِا‏ػٍى‏ٔطاق‏ٚاسغ‏ٌؼلاج‏
دٚيح‏الا‏ح‏ٌٍدٙاص‏اٌٙضّي‏يحذ‏ِٓ‏فائذذٙا..‏ِٚغ‏رٌه،‏فإْ‏سّيح‏٘زٖ‏الادٚيالاٌرٙاتاخ‏ِخرٍفح‏ِٓ
الأضيّاخ‏اٌّٛصػح‏في‏‏يرُ‏ذفؼيٍٙا‏ػٓ‏طشيك‏الاٌرٙاب‏اٌلاسريشٚيذيح‏‏ٌّضاداخ‏اٌرمٍيذيح‏ّساػذجاٌ
يّىٓ ‏أْ ‏ذرأثش ‏٘زٖ ‏الإٔضيّاخ ‏تؼٛاًِ ‏ِخرٍفح ‏ِثً ‏اٌؼّش ‏ٚاٌظشٚف‏‏تحيث‏خّيغ ‏أٔحاء ‏اٌدسُ
‏ِٓ‏اٌصؼة‏أْ‏ٔرٛلغ‏ِؼذلاخ‏اٌرحٛيً‏اٌثيٌٛٛخي.ذُ ‏ذطٛيش‏اسرشاذيديحتحيث‏.‏اٌصحيح‏ٚاٌدٕس
ً‏داخً‏اٌدضئ‏ٌرحشيش‏اٌذٚاء‏اسرخذِد‏اٌيح‏اٌرفاػ‏ٌٍذٚاء‏إٌشط‏.‏‏ذٚاء‏اٌّساػذخذيذج‏ٌرحٛيً‏اٌ
اٌؼٍّيح‏ذؼرّذ‏فمط‏‏اء‏اٌّساػذ‏,ٚحاخح‏لأضيُ‏اٌرحفيض‏ٌرفؼيً‏اٌذلا‏تٙزٖ‏اٌطشيمح‏.ِٓ‏اٌذٚاء‏اٌّساػذ
‏‏ػٍى‏اٌخطٛج‏اٌّحذدج‏ٌٍرفاػً‏داخً‏اٌدضئ.
 الاهذاف:
اٌّيفيٕاِيه‏‏حّض‏ذصٕيغ ‏ادٚيح ‏ِساػذج ‏ِٚشرشوح ‏ ‏ٌىً ‏ِٓاٌٙذف ‏اٌشئيسي ‏ٌؼٍّٕا ‏٘ٛ ‏
الاثاس ‏اٌسٍثيح ‏ٌٍّؼذج. ‏تالاضافح ‏ٌزٌه ‏,الادٚيح‏‏,خاٌيح ‏ِٓ ‏اٌطؼُ ‏اٌّش‏تحيث‏ذىْٛ‏.ٚاٌذيىٍٛفيٕان
‏يدة‏اْ‏يىْٛ‏ٌذيٙا ‏اٌمذسج ‏ٌٍرحًٍ‏اٌىيّيائي‏حّض‏اٌّيفيٕاِيه‏ٚاٌذيىٍٛفيٕاناٌّساػذج ‏اٌّمرشحح ‏
‏.ٌٚيس‏الأضيّي‏ٚلادسج‏ػٍى‏ذحشيش‏اٌذٚاء‏تشىً‏ِسيطش‏ػٍيٗ
 الطزٌقت:‏
الادٚيح‏اٌّساػذج‏الاٌٚيح‏ٚاٌّشرشوح‏اٌري‏ذُ‏ذصٕيؼٙا‏تاسرخذاَ‏ذفٕياخ‏‏دساسح‏ِٛاصفاخذُ‏اٌرأوذ‏ٚ
في ‏استؼح‏‏CLPHِٚؼذي ‏ذحًٍ ‏الادٚيح ‏ذّد‏دساسرٗ ‏ايضا ‏تاسرخذاَ ‏خٙاص ‏اي ‏اٌرحٍيً ‏اٌطيفي. ‏
‏.4.7Hpٚ‏lCHN1 ,5.2Hp ,5.5Hpِحاٌيً‏ِخرٍفح‏
 الٌخائج:
ذُ ‏ذصٕيغ ‏ادٚيح ‏ِساػذج ‏اٌٚيح ‏ِّيضج ‏ٌحّض‏اٌّيفيٕاِيه ‏ٚاٌذيىٍٛفيٕان.ٚوزٌه ‏ذُ ‏ذصٕيغ ‏ادٚيح‏
ِشرشوح ‏ِٓ ‏حّض‏اٌّيفيٕاِيه ‏ٚاٌذيىٍٛفيٕان ‏ِغ ‏اٌرشأيىساِيه ‏ذفرمش ‏ٌٍطؼُ ‏اٌّش.ٚتيٕد ‏ٔرائح‏
سخح‏الادٚيح‏اٌّساػذج ‏يرأثش‏تشذج‏ِٓ‏دحشويح‏الادٚيح‏ٌٍّشوثاخ‏اٌري‏ذُ‏ذصٕيؼٙا ‏اْ‏ِؼذي‏ذحًٍ‏
في‏دسخح‏حّٛضح‏‏دايّيثيً‏اِيِٓيفيٕاِيه‏‏ي‏حّض‏2/1t(ػّش‏إٌصف‏(واْ‏‏حّٛضح‏‏اٌٛسط.
اِا ‏تإٌسثح ‏ي‏. ‏2.5ٚ ‏‏2.2، ‏‏2.5دسخاخ ‏اٌحّٛضح ‏تيّٕا ‏واْ ‏ِسرمشا ‏ػٕذ ‏‏ساػح10اٌّؼذج ‏
ػٍى‏اٌرٛاٌي.‏في‏حيٓ‏أٔٗ‏‏7.5‏,0‏دسخح‏اٌحّٛضح‏ساػح‏في‏1،‏ 2/1t( 4 واْ‏( تيٕضيديىٍٛفيٕان‏
ِيفيٕاِيه‏ذشأيىساِيه‏‏ذحًٍ‏تسٌٙٛح‏ٌيٕرح‏‏وً‏.7.5ٚ‏‏2.2واْ‏ِسرمش‏ذّاِا‏في‏دسخح‏اٌحّٛضح‏
في ‏دسخح‏‏ٗفاْ ‏ذحٍٍ). ‏ِٚغ ‏رٌه، ‏0ِٓ ‏اٌذٚائيٓ ‏في ‏حّض‏اٌٙيذسٚوٍٛسيه(دسخح ‏اٌحّٛضح ‏
‏ٌٗ ‏في‏ػّش ‏إٌصف‏فاْ‏ذشأيىساِيه‏ديىٍٛفيٕاناِا ‏‏يىاد ‏يزوش.لا ‏, 4.7 2.2‏,‏2.5اٌحّٛضح ‏
‏ساػح.‏03‏٘ٛlCHN1
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